How have ELVN and VKTX total returns compared?

Over the past 5 years, ELVN delivered 24.57% and VKTX delivered 37.36% annualized total return. Past performance doesn't predict future results.

Enliven Therapeutics, Inc. (ELVN) vs Viking Therapeutics, Inc. (VKTX)

A side-by-side comparison of Enliven Therapeutics, Inc. and Viking Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ELVN

Enliven Therapeutics, Inc.

$3.03B

$42.39HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

VKTX

Viking Therapeutics, Inc.

$3.31B

$28.38HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — ELVN vs VKTX

growth of $100 · dividends reinvested · last 7y

ELVN -24.2% (-3.9%/yr)VKTX +615.9% (+32.5%/yr)VKTX compounded faster over this window

Log scale — wide-divergence pair

ELVN VKTX

ELVN vs VKTX: by the numbers

•VKTX is the larger company ($3.31B vs $3.03B market cap).

Metrics side by side

Valuation

Metric	ELVN	VKTX
P/B ratio	3.38	8.11

Profitability

Metric	ELVN	VKTX
Gross margin	0.00%	0.00%
Operating margin	0.00%	0.00%
Net margin	0.00%	0.00%
ROE	-11.83%	-130.98%
ROIC	-13.88%	-135.85%

Growth (annualized)

Metric	ELVN	VKTX
Total return CAGR (5Y)	24.57%	37.36%

Frequently asked

How have ELVN and VKTX total returns compared?: Over the past 5 years, ELVN delivered 24.57% and VKTX delivered 37.36% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ELVN analysis Full VKTX analysis Interactive comparison tool

Dig into the metrics

Enliven Therapeutics ROE Viking Therapeutics ROE Enliven Therapeutics operating margin Viking Therapeutics operating margin Enliven Therapeutics revenue growth Viking Therapeutics revenue growth Enliven Therapeutics free cash flow Viking Therapeutics free cash flow

Enliven Therapeutics & Viking Therapeutics appear in these rankings

Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.